01177 中國生物製藥
按盘价 
3.350 +0.060 (+1.824%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | 3.653% | 4.083% | 27.114% | 6.541% | 6.327% |
| 股东资金回报率 (%) | 7.745% | 8.473% | 62.113% | 17.485% | 12.506% |
| 资本运用回报率 (%) | 5.688% | 5.792% | 32.321% | 7.641% | 9.396% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | 80.954% | 79.863% | 80.150% | 78.085% | 79.672% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 27.790% | 25.073% | 22.638% | 28.758% | 28.873% |
| 税前边际利润率 (%) | 20.649% | 20.078% | 69.143% | 21.199% | 23.482% |
| 纯利率 (%) | 8.901% | 8.838% | 54.384% | 11.718% | 11.395% |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 1.053 X | 1.287 X | 1.532 X | 2.083 X | 3.067 X |
| 速动比率 (X) | 0.965 X | 1.171 X | 1.405 X | 1.911 X | 2.863 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 39.989% | 40.773% | 37.683% | 52.511% | 45.191% |
| 总债项 / 总资产比率 (%) | 19.779% | 21.825% | 20.015% | 30.099% | 22.967% |
| 净债项 / 总资产比率 (%) | 4.918% | 2.990% | 2.558% | 6.250% | -8.784% |
| 总债项 / 股东资金比率 (%) | 41.281% | 47.003% | 40.004% | 84.849% | 57.634% |
| 长期债项 / 股东资金比率 (%) | 4.505% | 14.314% | 18.264% | 75.406% | 53.020% |
| 净债项 / 股东资金比率 (%) | 10.266% | 6.440% | 5.113% | 17.619% | -22.043% |
| 净现金 / (债项) ($) | (31.28亿) | (19.16亿) | (15.49亿) | (29.51亿) | 32.95亿 |
| 每股净现金 / (债项) ($) | (0.166) | (0.102) | (0.082) | (0.156) | 0.175 |
| 总债项 / 资本运用比率 (%) | 30.685% | 31.840% | 26.810% | 39.181% | 29.315% |
| 利息盈利率 (X) | 11.924 X | 14.161 X | 61.180 X | 16.503 X | 25.747 X |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | 158.085日 | 134.354日 | 130.670日 | 124.617日 | 106.240日 |
| 应收贸易帐周转率日数 (日) | 63.727日 | 56.176日 | 48.474日 | 43.421日 | 42.445日 |
| 应付贸易帐周转率日数 (日) | 20.703日 | 21.119日 | 24.737日 | 28.997日 | 27.424日 |
| 备注： | 实时报价更新时间为03/12/2024 18:00 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB 3,017,162 |
| 增长率 | 139.689% |
| 每股盈利/(亏损) | RMB 0.164 |
| 每股账面资产净值 (¥) | RMB 1.748 |